Tilt Renewables Limited (NZX: TLT) Non-Binding Offers Received

Tilt Renewables Limited advises that it has received a number of non-binding indicative proposals to acquire the company, following the strategic review process being conducted by Tilt Renewables major shareholder, Infratil Limited.

The Board of Tilt Renewables has reviewed the proposals and decided to grant a number of parties access to due diligence material to enable these parties to prepare binding proposals.

The Board notes that participation in Infratil’s strategic review process is not a prerequisite to it considering any proposals in respect of Tilt Renewables.

There is no certainty that Tilt Renewables will receive binding proposals or that any proposals received will be recommended to shareholders by the Board.

Tilt Renewables is being advised by Lazard as financial adviser and Russell McVeagh and Ashurst as legal advisers.

Please see the link below for more details:

Non-Binding Offers Received

Source: Tilt Renewables Limited

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Meridian Energy monthly operating report for July 2022
Cannasouth to launch a pro-rata renounceable rights issue
August 12th Morning Report
2022 Annual Shareholders' Meeting & Director Nominations
Rakon 2022 Annual Meeting Chair's Address and Presentation
VHP - Full year results release
RAKON FY23 Earnings Guidance
August 11th Morning Report
Deferral of FDA consideration of enforcement discretion
MHJ - Response to ASX Query